SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials

J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):e30. doi: 10.1097/QAI.0000000000002875.

Michael J Peluso¹, Meghann C Williams¹, Danielle M Campbell^{2

3

4}, Lynda Dee^{2

3

5

6}, Jeff Taylor^{3

6

7

8}, Lynn H Ngo¹, Rebecca Hoh¹, Karine Dubé^{9

10}, John A Sauceda¹⁰, Steven G Deeks¹

¹ Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA.
² Delaney AIDS Research Enterprise (DARE) Community Advisory Board.
³ Martin Delaney Collaboratory Community Advisory Board.
⁴ Carles R. Drew University of Medicine and Science, Los Angeles, CA.
⁵ AIDS Action Baltimore, Baltimore, MD.
⁶ amfAR Institute for HIV Cure Research Community Advisory Board.
⁷ HIV + Aging Research Project (HARP-PS), Palm Springs, CA.
⁸ Antiviral Research Center (AVRC) Community Advisory Board, University of California San Diego (UCSD), San Diego, CA.
⁹ Gillings School of Public Health, University of North Carolina (UNC), Chapel Hill, NC.
¹⁰ Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, CA.

No abstract available

MeSH terms